The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Michael R. Zalutsky

Department of Radiology

Duke University Medical Center

Durham

NC 27710 USA

USA

[email]@mc.duke.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Radiology, Duke University Medical Center, Durham, NC 27710 USA, USA. 1997 - 2012

References

  1. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Zalutsky, M.R., Boskovitz, A., Kuan, C.T., Pegram, C.N., Ayriss, J., Wikstrand, C.J., Buckley, A.F., Lipp, E.S., Herndon, J.E., McLendon, R.E., Bigner, D.D. Nucl. Med. Biol. (2012) [Pubmed]
  2. Astatine-211: production and availability. Zalutsky, M.R., Pruszynski, M. Curr. Radiopharm (2011) [Pubmed]
  3. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Zalutsky, M.R., Reardon, D.A., Akabani, G., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Wong, T.Z., Bigner, D.D. J. Nucl. Med. (2008) [Pubmed]
  4. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Zalutsky, M.R., Reardon, D.A., Pozzi, O.R., Vaidyanathan, G., Bigner, D.D. Nucl. Med. Biol. (2007) [Pubmed]
  5. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. Zalutsky, M.R. J. Nucl. Med. (2006) [Pubmed]
  6. Current status of therapy of solid tumors: brain tumor therapy. Zalutsky, M.R. J. Nucl. Med. (2005) [Pubmed]
  7. Targeted radiotherapy of brain tumours. Zalutsky, M.R. Br. J. Cancer (2004) [Pubmed]
  8. Radioimmunotherapy with alpha-particle emitting radionuclides. Zalutsky, M.R., Pozzi, O.R. Quarterly J. Nuclear Medicine Molecular Imaging : Official Publication Italian Association Nuclear Medicine (aimn) [and] International Association Radiopharmacology (iar), [and] Section Society Radiopharmaceut... (2004) [Pubmed]
  9. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Zalutsky, M.R., Vaidyanathan, G. Curr. Pharm. Des. (2000) [Pubmed]
  10. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Zalutsky, M.R., Xu, F.J., Yu, Y., Foulon, C.F., Zhao, X.G., Slade, S.K., Affleck, D.J., Bast, R.C. Nucl. Med. Biol. (1999) [Pubmed]
  11. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Zalutsky, M.R., Stabin, M.G., Larsen, R.H., Bigner, D.D. Nucl. Med. Biol. (1997) [Pubmed]
 
WikiGenes - Universities